Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits
Penumbra (NYSE: PEN) presented seven new data sets demonstrating the effectiveness of their Computer Assisted Vacuum Thrombectomy (CAVT™) technology at the 2025 Society of Interventional Radiology Annual Meeting. The STRIKE-PE trial showed significant improvements in treating pulmonary embolism, with a 27.8% reduction in right ventricle/left ventricle ratio and 24.5% decrease in pulmonary artery pressures, while maintaining a low adverse event rate under 1%.
The STRIDE study demonstrated high limb salvage rates for lower-extremity acute limb ischemia. The THRIVE study revealed CAVT resulted in 26-46% shorter hospital stays and 46-75% higher home discharge rates compared to traditional treatments. For lower extremity venous thrombus treatment, CAVT showed 17% shorter hospital stays and 40% higher home discharge rates versus anticoagulation alone.
Penumbra (NYSE: PEN) ha presentato sette nuovi set di dati che dimostrano l'efficacia della loro tecnologia di Thrombectomia Vacuum Assistita da Computer (CAVT™) durante il Meeting Annuale della Società di Radiologia Interventistica del 2025. Il trial STRIKE-PE ha mostrato miglioramenti significativi nel trattamento dell'embolia polmonare, con una riduzione del 27,8% del rapporto ventricolo destro/ventricolo sinistro e una diminuzione del 24,5% delle pressioni arteriose polmonari, mantenendo un basso tasso di eventi avversi sotto l'1%.
Lo studio STRIDE ha dimostrato alti tassi di salvataggio degli arti per l'ischemia acuta degli arti inferiori. Lo studio THRIVE ha rivelato che il CAVT ha portato a soggiorni ospedalieri più brevi del 26-46% e tassi di dimissione a casa più elevati del 46-75% rispetto ai trattamenti tradizionali. Per il trattamento del trombo venoso degli arti inferiori, il CAVT ha mostrato soggiorni ospedalieri più brevi del 17% e tassi di dimissione a casa superiori del 40% rispetto all'anticoagulazione da sola.
Penumbra (NYSE: PEN) presentó siete nuevos conjuntos de datos que demuestran la eficacia de su tecnología de Trombectomía Asistida por Computadora (CAVT™) en la Reunión Anual de la Sociedad de Radiología Intervencionista de 2025. El ensayo STRIKE-PE mostró mejoras significativas en el tratamiento de la embolia pulmonar, con una reducción del 27,8% en la relación ventrículo derecho/ventrículo izquierdo y una disminución del 24,5% en las presiones de la arteria pulmonar, manteniendo una baja tasa de eventos adversos por debajo del 1%.
El estudio STRIDE demostró altas tasas de salvamento de extremidades para la isquemia aguda de las extremidades inferiores. El estudio THRIVE reveló que el CAVT resultó en estancias hospitalarias de 26-46% más cortas y tasas de alta a domicilio de 46-75% más altas en comparación con tratamientos tradicionales. Para el tratamiento del trombo venoso en las extremidades inferiores, el CAVT mostró estancias hospitalarias un 17% más cortas y tasas de alta a domicilio un 40% más altas en comparación con la anticoagulación sola.
페넘브라 (NYSE: PEN)는 2025년 개입 방사선학회 연례 회의에서 그들의 컴퓨터 보조 진공 혈전 제거술 (CAVT™) 기술의 효과를 입증하는 7개의 새로운 데이터 세트를 발표했습니다. STRIKE-PE 시험은 폐색전증 치료에서 의미 있는 개선을 보여주었으며, 우심실/좌심실 비율이 27.8% 감소하고 폐동맥 압력이 24.5% 감소했으며, 부작용 발생률은 1% 미만으로 유지되었습니다.
STRIDE 연구는 하지 급성 허혈에 대한 높은 사지 구제 비율을 입증했습니다. THRIVE 연구는 CAVT가 전통적인 치료법에 비해 병원에 머무는 기간을 26-46% 단축하고 퇴원률을 46-75% 높였음을 밝혔습니다. 하지 정맥 혈전 치료에서 CAVT는 항응고제 단독 치료에 비해 병원에 머무는 기간을 17% 단축하고 퇴원률을 40% 높였습니다.
Penumbra (NYSE: PEN) a présenté sept nouveaux ensembles de données démontrant l'efficacité de sa technologie de Thrombectomie Assistée par Ordinateur (CAVT™) lors de la Réunion Annuelle de la Société de Radiologie Interventionnelle de 2025. L'essai STRIKE-PE a montré des améliorations significatives dans le traitement de l'embolie pulmonaire, avec une réduction de 27,8% du rapport ventricule droit/ventricule gauche et une diminution de 24,5% des pressions artérielles pulmonaires, tout en maintenant un faible taux d'événements indésirables en dessous de 1%.
L'étude STRIDE a démontré des taux élevés de sauvetage des membres pour l'ischémie aiguë des membres inférieurs. L'étude THRIVE a révélé que le CAVT a entraîné des séjours hospitaliers 26-46% plus courts et des taux de sortie à domicile 46-75% plus élevés par rapport aux traitements traditionnels. Pour le traitement des thrombus veineux des membres inférieurs, le CAVT a montré des séjours hospitaliers 17% plus courts et des taux de sortie à domicile 40% plus élevés par rapport à l'anticoagulation seule.
Penumbra (NYSE: PEN) hat auf dem Jahreskongress der Gesellschaft für interventionelle Radiologie 2025 sieben neue Datensätze präsentiert, die die Wirksamkeit ihrer Computergestützten Vakuumthrombektomie (CAVT™)-Technologie demonstrieren. Die STRIKE-PE-Studie zeigte signifikante Verbesserungen bei der Behandlung von Lungenembolie, mit einer Reduktion des Verhältnisses von rechtem zu linkem Ventrikel um 27,8% und einem Rückgang des Drucks in der Lungenarterie um 24,5%, wobei die Rate unerwünschter Ereignisse unter 1% blieb.
Die STRIDE-Studie zeigte hohe Erhaltungsraten der Gliedmaßen bei akuter Ischämie der unteren Extremitäten. Die THRIVE-Studie ergab, dass CAVT zu 26-46% kürzeren Krankenhausaufenthalten und 46-75% höheren Entlassungsraten nach Hause im Vergleich zu traditionellen Behandlungen führte. Bei der Behandlung von venösen Thromben in den unteren Extremitäten zeigte CAVT 17% kürzere Krankenhausaufenthalte und 40% höhere Entlassungsraten nach Hause im Vergleich zur alleinigen Antikoagulation.
- Clinical success: 27.8% reduction in right ventricle/left ventricle ratio
- High safety profile with under 1% major adverse event rate
- 99.1% limb salvage rate in LE-ALI cases
- 26-46% reduction in hospital length of stay
- 40-75% higher rate of home discharges
- None.
Insights
Penumbra's presentation of seven clinical data sets for its Computer Assisted Vacuum Thrombectomy (CAVT) technology represents significant validation of their thrombectomy platform. The STRIKE-PE study results are particularly compelling with a
The median device time of just 22.5 minutes indicates remarkable procedural efficiency that directly benefits patients by reducing time under anesthesia and procedure-related complications. For clinicians, this efficiency translates to more cases treated per day and less procedural fatigue.
The STRIDE study's high limb salvage rates in both in-stent and native-vessel thrombosis patients expand CAVT's clinical utility beyond pulmonary applications into peripheral vascular disease - a substantial market opportunity. The technology's demonstrated effectiveness across multiple clot locations positions Penumbra's platform as a versatile solution for interventionalists.
The recognition of STRIKE-PE with the JVIR Outstanding Clinical Study Award adds considerable credibility, which typically accelerates technology adoption among evidence-focused physicians. As one of the largest PE trials with long-term functional and quality of life data, STRIKE-PE establishes Penumbra as a leader in evidence-based device development.
The resource utilization findings presented by Penumbra make a compelling economic case for CAVT adoption. The THRIVE study demonstrates a
Similarly, the
The
Penumbra's planned presentations targeting hospital executives indicates strategic positioning of CAVT as both a clinical and financial solution. As healthcare systems increasingly adopt value-based care models that incentivize both outcomes and efficiency, technologies that demonstrate dual benefits receive prioritized adoption. The comprehensive economic data across multiple thrombotic conditions creates a persuasive value proposition for hospital value analysis committees and could accelerate CAVT's market penetration across multiple service lines.
"With this growing body of evidence across several disease states, we are continuously demonstrating the wide-ranging impact CAVT can have as a frontline option on patient outcomes, quality of life and resource utilization in the healthcare system," said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra. "This extensive research and innovation in clot management underscores our commitment to save lives, improve patient outcomes and positively impact healthcare economics."
STRIKE-PE Continued to Showcase CAVT's Speed, Safety and Simplicity in the Treatment of PE
All four presentations featuring interim results of STRIKE-PE demonstrated CAVT is a safe, fast and effective procedure for the treatment of pulmonary embolism (PE). Most notably, the subgroup analysis that evaluated the use of Lightning Flash™ only to treat PE showed:
- Significant reduction of right ventricle/left ventricle ratio by
27.8% and a decrease in mean pulmonary artery pressures by24.5% - Low overall major adverse event rate of under
1% - Fast device time of 22.5 minutes (median)
Enrolling up to 1,500 patients, STRIKE-PE is one of the largest and most comprehensive PE trials with long-term functional and quality of life data. It was recognized at SIR for winning the JVIR Outstanding Clinical Study Award for the 2024 publication.
STRIDE Subset Analysis Showed High Limb Salvage Rate in LE-ALI with CAVT Use
A subset analysis of the STRIDE study demonstrated that when CAVT was used to address lower-extremity acute limb ischemia (LE-ALI) in both in-stent thrombosis and native-vessel thrombosis patients, the procedure was safe and effective with high target limb salvage rates at 30 days.
CAVT Decreased Healthcare Resource Utilization for LE-ALI and Lower Extremity Venous Thrombus
The results of the THRIVE study, a retrospective analysis of resource use and clinical outcomes with LE-ALI that compared CAVT use vs. embolectomy alone and vs. embolectomy with bypass, showed that CAVT was associated with:
99.1% limb salvage rate- 26
-46% shorter total hospital length of stay - 46
-75% higher rate of patients discharged home
Additionally, in a retrospective analysis evaluating CAVT use compared to anticoagulation alone to manage lower extremity venous thrombus, the results showed that CAVT was associated with:
17% shorter total hospital length of stay40% higher rate of patients discharged home
These retrospective studies utilized the Vizient Clinical Data Base to identify patients with LE-ALI and lower extremity venous thrombus, respectively.
Separate from the SIR Annual Scientific Meeting, health economic data will be presented at other upcoming conferences showing hospital executives and leaders the significant positive economic benefits to the healthcare system of using CAVT in arterial and venous cases.
For more information about the CAVT SIR presentations, please visit: www.penumbrainc.com/sir-2025.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.
Important Safety Information
Additional information about Penumbra's products can be located on Penumbra's website at https://www.penumbrainc.com/providers. Caution: Federal (
The clinical results presented herein are for informational purposes only, and may not be predictive for all patients. Individual results may vary depending on patient-specific attributes and other factors.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 18, 2025. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Contact | |
Jennifer Heth | Parinaz Farzin |
Penumbra, Inc | Merryman Communications |
510-995-9791 | 310.600.6746 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/seven-new-data-sets-demonstrate-penumbras-computer-assisted-vacuum-thrombectomy-cavt-technology-is-safe-fast-and-effective-improves-patient-outcomes-and-delivers-healthcare-resource-benefits-302417699.html
SOURCE Penumbra, Inc.
FAQ
What are the key findings from Penumbra's STRIKE-PE trial for CAVT technology?
How does Penumbra's CAVT technology impact hospital length of stay for LE-ALI patients?
What are the discharge outcomes for PEN's CAVT technology in venous thrombus treatment?
How effective is Penumbra's CAVT for limb salvage in acute limb ischemia?
